PhD Scientific Days 2023

Clinical Medicine - Posters J

A reduction in body mass index (BMI) is a potential predictor of functional progression in patients with pulmonary fibrosis associated with connective tissue disease.

Előadó neve

Dr. Nagy, Alexandra

Neptun code

EQIFO

Előadó munkahelye

Semmelweis University, Department of Pulmonology

Előadó telefonszáma

06302630563

Előadó e-mail címe

nagy.alexandra0718@gmail.com

Az előadás címe

A reduction in body mass index (BMI) is a potential predictor of functional progression in patients with pulmonary fibrosis associated with connective tissue disease.

Szerző(k) neve és munkahelye

Authors: Alexandra Nagy, Bernadett Mák, Tamás Nagy, Nóra Melinda Tóth, Krisztina Vincze, Noémi Eszes, Anikó Bohács,Veronika Müller
Affiliation: Department of Pulmonology, Semmelweis University

Bemutatás módja

Poszter

Szekció

Clinical Medicine - Posters J

Language of the presentation

Hungarian

Preferred session

Clinical Medicine

Összefoglaló szövege

Introduction: Interstitial lung disease (ILD) is a severe complication of connective tissue diseases (CTD) that often presents as progressive pulmonary fibrosis (PPF).
Aims: In this study, we aimed to assess CTD-ILD cases reviewed by a multidisciplinary team of experts for functional progression ((f)PPF).
Methods: Between July 2019 and October 2020, our team reviewed 217 cases, with CTD-ILD accounting for 17.5% of cases. Baseline pulmonary symptoms, body mass index (BMI), and lung function were evaluated for all cases. Out of the 38 confirmed CTD-ILD cases, functional follow-up data were available for 29 cases.
Results: Most CTD-ILD patients were women (73.7%) and non-smokers (60.5%), with cough (68.4%), dyspnea (60.5%), and joint pain (60.5%) being the most common symptoms. Lung function tests revealed a mild restrictive ventilatory disorder and a decrease in diffusion (forced vital capacity % (FVC%) : 81.9 ± 23.9, diffusing capacity of the lung for carbon monoxide % (DLCO%) 73.3 ± 22.6 %). Among the 29 cases with follow-up data, 10 cases met the functional progression criteria outlined in the new American Thoracic Society / European Respiratory Society guideline. The rate of decline in FVC% and DLCO% was higher in the functional (f)PPF group (Group 1) compared to the stable group (Group 2) during follow-up. Weight loss was also more prominent in Group 1 (Δbody mass index 2.4 vs. 1.3 kg/m2, p=0.02) compared to Group 2.
Conclusion: Overall, 26.3% of CTD-ILD patients experienced functional progression. Regular monitoring of body weight and lung function is crucial for timely recognition of progression.
Funding: SUPPORTED BY THE ÚNKP-22-3-I NEW NATIONAL EXCELLENCE PROGRAM OF THE MINISTRY FOR CULTURE AND INNOVATION FROM THE SOURCE OF THE NATIONAL RESEARCH, DEVELOPMENT AND INNOVATION FUND.

University and Doctoral School

Semmelweis University, Károly Rácz Doctoral School of Clinical Medicine

Supervisor

Prof. Veronika Müller M.D., Ph.D., D.Sc.

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

6406

Start

10:54

End

10:59

Authors (legacy)

Authors: Alexandra Nagy, Bernadett Mák, Tamás Nagy, Nóra Melinda Tóth, Krisztina Vincze, Noémi Eszes, Anikó Bohács,Veronika Müller
Affiliation: Department of Pulmonology, Semmelweis University